- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06125951
Effect van 10 mg Xananamem op dementie als gevolg van de ziekte van Alzheimer (XanaMIA)
Een fase 2b, dubbelblinde, placebogecontroleerde, parallelle groepen, 36 weken durende, 2-armige studie om de veiligheid, verdraagbaarheid en werkzaamheid van Xanamem® 10 mg per dag te beoordelen bij patiënten met milde of matige dementie als gevolg van de ziekte van Alzheimer
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Darlinghurst, New South Wales, Australië
- ACW Investigative Site 106
-
Erina, New South Wales, Australië
- ACW Investigative Site 103
-
Kogarah, New South Wales, Australië
- ACW Investigative Site 102
-
Macquarie Park, New South Wales, Australië
- ACW Investigative Site 107
-
Newcastle, New South Wales, Australië
- ACW Investigative Site 111
-
-
Queensland
-
Birtinya, Queensland, Australië
- ACW Investigative Site 113
-
Chermside, Queensland, Australië
- ACW Investigative Site 105
-
-
South Australia
-
Bedford Park, South Australia, Australië
- ACW Investigative Site 114
-
Woodville South, South Australia, Australië
- ACW Investigative Site 110
-
-
Victoria
-
Carlton, Victoria, Australië
- ACW Investigative Site 115
-
Ivanhoe, Victoria, Australië
- ACW Investigative Site 101
-
Malvern, Victoria, Australië
- ACW Investigative Site 108
-
Parkville, Victoria, Australië
- ACW Investigative Site 112
-
-
Western Australia
-
Nedlands, Western Australia, Australië
- ACW Investigative Site 104
-
West Perth, Western Australia, Australië
- ACW Investigative Site 109
-
-
-
-
California
-
Carlsbad, California, Verenigde Staten, 92011
- ACW Investigative Site 218
-
Sherman Oaks, California, Verenigde Staten, 91403
- ACW Investigative Site 209
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- ACW Investigative Site 211
-
Englewood, Colorado, Verenigde Staten, 80113
- ACW Investigative Site 208
-
-
Florida
-
Delray Beach, Florida, Verenigde Staten, 33445
- ACW Investigative Site 203
-
Miami, Florida, Verenigde Staten, 33176
- ACW Investigative site 201
-
New Port Richey, Florida, Verenigde Staten, 34652
- ACW Investigative site 202
-
Orlando, Florida, Verenigde Staten, 32803
- ACW Investigative site 204
-
The Villages, Florida, Verenigde Staten, 32162
- ACW Investigative site 205
-
-
Georgia
-
Decatur, Georgia, Verenigde Staten, 30030
- ACW Investigative Site 207
-
-
New Jersey
-
Marlton, New Jersey, Verenigde Staten, 08053
- ACW Investigative Site 206
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- ACW Investigative Site 214
-
Staten Island, New York, Verenigde Staten, 10314
- ACW Investigative Site 219
-
-
Ohio
-
Dayton, Ohio, Verenigde Staten, 45459
- ACW Investigative Site 210
-
Independence, Ohio, Verenigde Staten, 44131
- ACW Investigative Site 217
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97225
- ACW Investigative Site 212
-
-
Rhode Island
-
East Providence, Rhode Island, Verenigde Staten, 02914
- ACW Investigative Site 216
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78757
- ACW Investigative Site 220
-
-
Washington
-
Bellevue, Washington, Verenigde Staten, 98007
- ACW Investigative Site 215
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Male or female aged 50 years or older, inclusive at the time of Screening.
-
Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:
- Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
- Mini-mental state examination (MMSE) score of 18 to 26
- Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
- Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
-
If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
-
Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
-
Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
-
Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
-
Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.
Exclusion Criteria:
- Use of anti-amyloid or anti-tau antibody within 6 months.
- Diagnosis of a non-AD dementia including traumatic brain injury.
- Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
- Participation in another clinical trial of a drug or device
- Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
- Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
- Clinical diagnosis of Type I or Type II diabetes requiring insulin.
- Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
- Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
- Participants with a history of clinically significant drug abuse or addiction in the past 2 years
- Evidence or history of alcohol abuse
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: 10 mg Xanamem
10 mg Xanamem tablet, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Andere namen:
|
|
Placebo-vergelijker: Placebo
Placebo tablet, to be administered orally once every morning with or without food |
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient. |
|
Experimenteel: Open label phase
Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
Tijdsspanne: 36 weeks
|
Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement. |
36 weeks
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
Tijdsspanne: 36 weeks
|
Incidence and severity of TEAEs |
36 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Global Program Lead, Actinogen Medical Ltd
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neoplasmata
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neurocognitieve stoornissen
- Tauopathieën
- Neurodegeneratieve ziekten
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Lymfoom, non-Hodgkin
- Lymfoom
- Hemische en lymfatische ziekten
- Ziekte van Alzheimer
- Lymfoom, folliculair
- Dementie
- UE2343
Andere studie-ID-nummers
- ACW0009
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .